A Multicenter Phase II Study with Triptorelin (Sustained-Release LHRH Agonist) in Advanced or Recurrent Endometrial Carcinoma: A French Anticancer Federation Study
| Autor: | Thierry Lesimple, J.L. Achard, D. Lebrun, Bruno Coudert, Jean-Paul Guastalla, P. Vennin, J. Blumberg, N. Callet, P. Chinet-Charrot, Catherine Lhommé, S. Ispas, J.E. Couette, Elisabeth Luporsi, J. Chauvergne |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Oncology Agonist medicine.medical_specialty Antineoplastic Agents Hormonal medicine.drug_class medicine.medical_treatment Phases of clinical research Endometrium Follicle-stimulating hormone Internal medicine medicine Carcinoma Humans Aged Aged 80 and over Response rate (survey) Chemotherapy Triptorelin Pamoate business.industry Obstetrics and Gynecology Luteinizing Hormone Middle Aged medicine.disease Triptorelin Endometrial Neoplasms Surgery medicine.anatomical_structure Disease Progression Female France Follicle Stimulating Hormone Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Gynecologic Oncology. 75:187-193 |
| ISSN: | 0090-8258 |
| DOI: | 10.1006/gyno.1999.5538 |
| Popis: | The objective of this phase II multicenter study was to assess the efficacy and tolerance of triptorelin (a sustained-release LHRH agonist) in advanced or recurrent endometrial cancer. A total of 101 monthly intramuscular injections were administered to 24 eligible patients (median number/patient = 3; range 1-12). Mainly due to progression, only 16 patients received 3 or more injections. Among the 23 evaluable patients, 1 complete and 1 partial response (response rate of 8.7%) and 5 disease stabilizations were observed, often of long duration, but never in an irradiated area or after progestogens treatment failure. Median survival for eligible patients was 7.2 months (range: 1-36 months). Only grade 1 toxicities possibly related to the treatment were observed in 4 patients. In conclusion, triptorelin was safe, well tolerated, and easily manageable, and the very low toxicity did not impair the quality of life in these patients with a very poor prognosis. Although the response rate was disappointing, several patients showed early evidence of efficacy which may be of long duration. Response rates range between 0 and 45% in different published studies. Additional studies with stricter inclusion criteria and a larger sample size are necessary to better evaluate the role of LHRH agonists in endometrial adenocarcinomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect